Effect of Camostat for Kidney Protection in Chronic Kidney Disease (CamKid).

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508516-34-00

Enrollment

Registered

2024-03-18

Start date

2024-10-30

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease with proteinuria

Brief summary

Urine sodium excretion, Water excretion, Body Composition Monitor / weight, Home blood pressure

Detailed description

Urine protease activity: zymography + protease activity assay, Tubular complement activation: Urine total C3, C3a, C5a, MAC-sC5b-9, C3dg, MBL, Urine microvesicles: gammaENaC cleavage and complement deposition (sC5b-9), 24 hours urine albumin excretion, Plasma concentration of renin, NT-proBNP, angiotensin II and aldosterone

Interventions

DRUGCAMOSTAT MESILATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Urine sodium excretion, Water excretion, Body Composition Monitor / weight, Home blood pressure	—

Secondary

Measure	Time frame
Urine protease activity: zymography + protease activity assay, Tubular complement activation: Urine total C3, C3a, C5a, MAC-sC5b-9, C3dg, MBL, Urine microvesicles: gammaENaC cleavage and complement deposition (sC5b-9), 24 hours urine albumin excretion, Plasma concentration of renin, NT-proBNP, angiotensin II and aldosterone	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026